1. Pink Sheet

OxyContin Abuse Deterrent Formulation Voted Beneficial By FDA Panel, But Questions Remain

 
• By Brenda Sandburg

Label change is one option after US advisory committee review of Purdue’s postmarketing studies concludes reformulated OxyContin ‘meaningfully reduced abuse’ by non-oral routes, but finds there is not evidence to show such reduction via all routes or that ADF reduced risk of opioid overdose. 

Pills
FDA advisory committee gives mixed reviews to OxyContin ADF postmarketing studies • Source: Shutterstock

A US Food and Drug Administration advisory panel concluded that Purdue Pharma L.P.’s abuse deterrent formulation of OxyContin “meaningfully reduced” its abuse by non-oral routes. But members found that the reformulation did not reduce opioid overdose and questioned the overall impact of the reformulation on the opioid crisis.

It is unclear what impact their conclusions will have on OxyContin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers